Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codeine-N-Oxide is a semi-synthetic opiate and an active metabolite of codeine formed by oxidation. It belongs to the class of organic compounds known as morphinans. Codeine-N-Oxide acts as a weak opioid agonist at the mu-opioid receptor but is considerably less potent than its parent compound, codeine. Like other N–oxides in this chemical family (e.g., morphine-N–oxide), it has been studied as a potential pharmaceutical drug but currently has no accepted medical use and is classified as a Schedule I controlled substance in the United States due to its high abuse potential and lack of recognized safety or efficacy[1][2][4]. It may be found as an impurity or degradation product in some pharmaceutical preparations containing codeine[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine-n-oxide.